192374-14-4

192374-14-4 structure

Name: (S,S)-Hydroxy Bupropion
Chemical Name: (2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethylmorpholin-2-ol
CAS Number: 192374-14-4
Molecular Formula: C₁₃H₁₈ClNO₂
Molecular Weight: 255.74
Catalog: Signaling Pathways Membrane Transporter/Ion Channel Monoamine Transporter
Create Date: 2018-12-17 08:34:36
Modify Date: 2026-07-01 21:07:25
Radafaxine ((S,S)-Hydroxybupropion) is an antidepressant. Radafaxine blocks dopamine transporters (DAT). Radafaxine is an active metabolite of Bupropion[1][2].

Name	(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethylmorpholin-2-ol
Synonyms	(2S,3S)-2-(3-Chlorophenyl)-3,5,5-trimethyl-2-morpholinol hydrochloride (1:1) RADAFAXINE HYDROCHLORIDE (RS,RS)-Hydroxybupropion (S)-Hydroxybupropion (2S,3S)-2-Hydroxy-2-(3'-chlorophenyl)-3,5,5-trimethylmorpholine (2S,3S)-2-(3-CHLORO-PHENYL)-3,5,5-TRIMETHYL-MORPHOLIN-2-OL HYDROCHLORIDE 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, (2S,3S)-, hydrochloride (1:1) Radafaxine (S,S)-Hydroxybupropion GW 353162A (S,S)-2-(3'-chlorophenyl)-3,5,5-trimethylmorpholine-2-ol (2S-cis)-2-(3-Chlorophenyl)-3,5,5-triMethyl 2-Morpholinol,2-(3-chlorophenyl)-3,5,5-trimethyl-,(2S,3S) Radafaxine hydrochloride (2S,3S)-hydroxybupropion 2-MORPHOLINOL, 2-(3-CHLOROPHENYL)-3,5,5-TRIMETHYL-, HYDROCHLORIDE, (2S,3S) (2S,3S)-2-(3-Chlorophenyl)-3,5,5-triMethyl-2-Morpholinol Radafaxine [INN] (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol

Description	Radafaxine ((S,S)-Hydroxybupropion) is an antidepressant. Radafaxine blocks dopamine transporters (DAT). Radafaxine is an active metabolite of Bupropion[1][2].
Related Catalog	Research Areas >> Neurological Disease Signaling Pathways >> Membrane Transporter/Ion Channel >> Monoamine Transporter
References	[1]. Volkow ND, et al. The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects. Biol Psychiatry. 2005 Mar 15;57(6):640-6. [2]. Xu H, et al. Stereoselective analysis of hydroxybupropion and application to drug interaction studies. Chirality. 2007 Mar;19(3):163-70.